Head-to-head · WeighScore
Roen Rx vs RxSpan MD
By GLP-1 ScorecardUpdated
Score comparison
RxSpan MD has the higher recorded score — 84.3/100 to 55.4/100.
RxSpan MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. RxSpan MD's live catalog lists brand-name GLP-1 drugs, while its homepage also advertises compounded plans; confirm the actual product and total price before enrolling.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Roen Rx | RxSpan MD |
|---|---|---|
| WeighScore | 55.4/100 | 84.3/100 |
| Grade | C | B |
| Site position | #489 | #5 |
| Semaglutide | $151/mo (3-month plan, plus a separate fee, compounded) | Current compounded quote unconfirmed |
| Tirzepatide | $216/mo (3-month offer, plus a separate fee, compounded) | Current compounded quote unconfirmed |
| Coverage | Coverage not published | Confirm treatment availability during intake |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #489 · C
FDAWarning letter issued to Roen Health, Inc. dba RoenRx in June 2026. See the FDA warning-letter database.
Strengths
- Insurance coordination for eligible branded prescriptions
- General membership and separate medication-included bundles
- Dedicated wellness coaching and secure messaging
- Quarterly compounded medication offers, with separate care fees to confirm
What to consider
- Confirm treatment-specific state eligibility and assigned clinician/pharmacy
- Insurance coverage and a $25 copay are not guaranteed
- General membership excludes medication; separate bundles include it with possible higher-dose extras
- Weight-loss coaches are not licensed dietitians or nutritionists
- Full ineligibility-refund advertising differs from general nonrefundable fees; confirm the selected exception
- FDA issued Roen Health, Inc. dba RoenRx a warning letter in June 2026; the letter is public in FDA's warning-letter database
Site position #5 · B
Strengths
- Current public catalog lists Ozempic, Wegovy, Mounjaro and Zepbound
- Public terms describe independent healthcare providers
- Homepage describes messaging and care-team appointments
What to consider
- Homepage advertises compounded plans that the current catalog did not substantiate
- Current oral GLP-1 availability is unconfirmed
- Prior compounded prices are not a current quote; selected dose, supply, pharmacy and fee inclusions need confirmation
- Public terms do not establish unused prepaid-treatment refund amounts
Featured provider
RxSpan MD
RxSpan MD scores 84.3/100 (B). RxSpan MD's live catalog lists brand-name GLP-1 drugs, while its homepage also advertises compounded plans; confirm the actual product and total price before enrolling.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.